A simple search of PubMed reveals striking insight. Querying the term prescribing yields 44 379 hits. In contrast, deprescribing yields only 672. Completing this exercise for a neurological condition such as epilepsy prescribing and epilepsy deprescribing yields similar results: 408 hits for the former and 3 for the latter. While this search is clearly overly simplistic, it illustrates a crucial point: attention is tremendously imbalanced.
What is the result? Half of US adults older than 65 years take 5 or more medications.1 It is no surprise that one survey found 67% of patients wanted to reduce their number of daily pills and 92% would be willing to stop a medication if their physician said it was possible.1 The emerging field of deprescribing—the systematic process of discontinuing drugs where harms outweigh benefits in the context of an individual patient’s values—seeks to rescue patients and clinicians alike.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Terman SW, Lamberink HJ, Braun KPJ. Deprescribing in Epilepsy: Do No Harm. JAMA Neurol. 2020;77(6):673–674. doi:10.1001/jamaneurol.2020.0473
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: